<DOC>
	<DOCNO>NCT00692770</DOCNO>
	<brief_summary>To evaluate efficacy safety sorafenib versus placebo adjuvant treatment Hepatocellular Carcinoma ( HCC ) potentially curative treatment ( surgical resection local ablation ) .</brief_summary>
	<brief_title>Sorafenib Adjuvant Treatment Prevention Of Recurrence Hepatocellular Carcinoma ( STORM )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Subjects undergone surgical resection local ablation ( PEI percutaneous intraoperative RFA ) treatment HCC curative intent within 4 month stag potentially curative treatment . A maximum 2 local ablation course may administer time period . At least 3 week ( 21 day ) 7 week ( 49 day ) , resection last local ablation course , CT/MRI scan date Male female subject &gt; /= 18 year age Confirmation CR ( absence residual tumor curative treatment ) , eligibility scan independent radiological review . For subject undergoing surgical resection pathology proven complete removal tumor . Intermediate High Risk recurrence assess tumor characteristic . ChildPugh score 5 7 point . A ChildPugh score 7 point allow absence ascites . ECOG Performance Status 0 . Adequate bone marrow , liver renal function Recurrent HCC ChildPugh score 7 point presence ascites . Low risk recurrence curative treatment History cardiovascular disease History HIV infection Active clinically serious infection ( &gt; grade 2 NCICTCAE version 3.0 ) Subjects seizure disorder require medication ( steroids antiepileptic ) Subjects evidence history bleed diathesis Subjects undergoing renal dialysis Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry define sign informed consent.. Uncontrolled ascites ( define easily control diuretic treatment ) Encephalopathy History GI bleed within 30 day randomization . Subjects history esophageal varix bleed follow effective therapy and/or treatment prevent bleed recurrence . Prior anti cancer therapy treatment HCC ( include sorafenib molecular therapy ) exclude . Major surgery within 4 week start study define sign informed consent , except surgical resection local ablation HCC . Investigational drug therapy outside trial within 4 week study entry , define signing informed consent . Liver transplantation , include patient transplant list intention transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Surgical resection</keyword>
	<keyword>Ablation</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Adjuvant therapy</keyword>
	<keyword>Liver cancer</keyword>
	<keyword>HCC</keyword>
	<keyword>STORM</keyword>
</DOC>